SCHEMBL8920975

SCHEMBL8920975

CC(C)(CO)C(=O)C(=O)N1CCCCC1C(=O)O

nearest known ligand 0.57

Predicted protein targets (top 4)

geneUniProtsupporting neighboursconfidence
FKBP1A P62942 11/20 0.57
LMNA P02545 1/20 0.52
CYP2C19 P33261 1/20 0.52
HSD17B10 Q99714 1/20 0.52

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2767842 1.00 FKBP1A (0.57) FKBP1ALMNACYP2C19HSD17B10
SCHEMBL3330557 0.95 LMNA (0.57) FKBP1ALMNACYP2C19HSD17B10
SCHEMBL4675555 0.88 FKBP1A (0.72) FKBP1A
SCHEMBL5966171 0.88 FKBP1A (0.72) FKBP1A
SCHEMBL499064 0.88 FKBP1A (0.72) FKBP1A
SCHEMBL7755136 0.85 FKBP1A (0.58) FKBP1ALMNACYP2C19HSD17B10
SCHEMBL8587480 0.84 FKBP1A (0.80) FKBP1A
SCHEMBL499268 0.84 FKBP1A (0.80) FKBP1A
SCHEMBL5966065 0.84 FKBP1A (0.57) FKBP1ALMNACYP2C19HSD17B10
SCHEMBL5966112 0.84 FKBP1A (0.57) FKBP1ALMNACYP2C19HSD17B10

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20240239810-A1 RAPAFUCIN DERIVATIVE COMPOUNDS AND METHODS OF USE THEREOF THE JOHNS HOPKINS UNIVERSITY 2024-07-18 US disclosed
US-11945827-B2 Rapafucin derivative compounds and methods of use thereof THE JOHNS HOPKINS UNIVERSITY (US) 2024-04-02 US disclosed
US-20230000996-A1 RAPAFUCIN DERIVATIVE COMPOUNDS AND METHODS OF USE THEREOF THE JOHNS HOPKINS UNIVERSITY 2023-01-05 US disclosed
US-11066416-B2 Rapafucin derivative compounds and methods of use thereof THE JOHNS HOPKINS UNIVERSITY (US) 2021-07-20 US disclosed
WO-2021067439-A1 RAPAFUCIN DERIVATIVE COMPOUNDS AND METHODS OF USE THEREOF THE JOHNS HOPKINS UNIVERSITY (US) 2021-04-08 WO disclosed
US-20210094933-A1 RAPAFUCIN DERIVATIVE COMPOUNDS AND METHODS OF USE THEREOF THE JOHNS HOPKINS UNIVERSITY 2021-04-01 US disclosed
US-20200040004-A1 RAPAFUCIN DERIVATIVE COMPOUNDS AND METHODS OF USE THEREOF RAPAFUSYN PHARMACEUTICALS, INC. 2020-02-06 US disclosed
US-20160333054-A1 SMALL MOLECULE COMPOSITE SURFACES AS INHIBITORS OF PROTEIN-PROTEIN INTERACTIONS NIH - DEITR 2016-11-17 US disclosed
US-9260484-B2 Small molecule composite surfaces as inhibitors of protein-protein interactions OHIO STATE INNOVATION FOUNDATION (US) 2016-02-16 US disclosed
US-20140200186-A1 SMALL MOLECULE COMPOSITE SURFACES AS INHIBITORS OF PROTEIN-PROTEIN INTERACTIONS NIH - DEITR 2014-07-17 US disclosed
WO-1997031899-A1 SYNTHETIC DERIVATIVES OF RAPAMYCIN AS MULTIMERISING AGENTS FOR CHIMERIC PROTEINS WITH IMMUNOPHILIN DERIVED DOMAINS ARIAD GENE THERAPEUTICS, INC. (US) 1997-09-04 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-11066416-B2 Rapafucin derivative compounds and methods of use thereof RICTOR, FKBP14, MTOR FKBP1A 9/4885LMNA 4788/4885CYP2C19 3397/4885
US-20140200186-A1 SMALL MOLECULE COMPOSITE SURFACES AS INHIBITORS OF PROTEIN-PROTEIN INTERACTIONS PAIP1, ECPAS, AIP FKBP1A 2208/4885LMNA 3463/4885CYP2C19 4481/4885
US-20200040004-A1 RAPAFUCIN DERIVATIVE COMPOUNDS AND METHODS OF USE THEREOF RICTOR, FKBP14, MTOR FKBP1A 9/4885LMNA 4788/4885CYP2C19 3397/4885
US-20230000996-A1 RAPAFUCIN DERIVATIVE COMPOUNDS AND METHODS OF USE THEREOF RICTOR, FKBP14, MTOR FKBP1A 9/4885LMNA 4788/4885CYP2C19 3397/4885
US-20210094933-A1 RAPAFUCIN DERIVATIVE COMPOUNDS AND METHODS OF USE THEREOF RICTOR, FKBP14, MTOR FKBP1A 9/4885LMNA 4788/4885CYP2C19 3397/4885
US-20160333054-A1 SMALL MOLECULE COMPOSITE SURFACES AS INHIBITORS OF PROTEIN-PROTEIN INTERACTIONS PAIP1, ECPAS, AIP FKBP1A 2208/4885LMNA 3463/4885CYP2C19 4481/4885
US-11945827-B2 Rapafucin derivative compounds and methods of use thereof RICTOR, FKBP14, MTOR FKBP1A 9/4885LMNA 4788/4885CYP2C19 3397/4885
US-20240239810-A1 RAPAFUCIN DERIVATIVE COMPOUNDS AND METHODS OF USE THEREOF RICTOR, MTOR, FKBP14 FKBP1A 10/4885LMNA 4818/4885CYP2C19 3710/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.